The Histone Deacetylase 1 and 2 (HDAC1/2) Inhibitor ACY-957: Impact of Dosing Schedule on Pharmacokinetics (PK), Pharmacodynamics (PD), Hematopoietic Toxicity, and Gamma Globin (HBG,.) Expression in Monkey

Chonkar Apurva; Jarpe Matthew; Bhol Kailash; Jones Simon S.; Shearstone Jeffrey R.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >The Histone Deacetylase 1 and 2 (HDAC1/2) Inhibitor ACY-957: Impact of Dosing Schedule on Pharmacokinetics (PK), Pharmacodynamics (PD), Hematopoietic Toxicity, and Gamma Globin (HBG,.) Expression in Monkey

【24h】

The Histone Deacetylase 1 and 2 (HDAC1/2) Inhibitor ACY-957: Impact of Dosing Schedule on Pharmacokinetics (PK), Pharmacodynamics (PD), Hematopoietic Toxicity, and Gamma Globin (HBG,.) Expression in Monkey

机译：组蛋白脱乙酰基酶1和2（HDAC1 / 2）抑制剂ACY-957：给药时间表对猴子体内药代动力学（PK），药效学（PD），造血毒性和伽马球蛋白（HBG）表达的影响

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共8页
作者
Chonkar Apurva; Jarpe Matthew; Bhol Kailash; Jones Simon S.; Shearstone Jeffrey R.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. The Histone Deacetylase 1 and 2 (HDAC1/2) Inhibitor ACY-957: Impact of Dosing Schedule on Pharmacokinetics (PK), Pharmacodynamics (PD), Hematopoietic Toxicity, and Gamma Globin (HBG,.) Expression in Monkey [J] . Chonkar Apurva, Jarpe Matthew, Bhol Kailash, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：组蛋白脱乙酰基酶1和2（HDAC1 / 2）抑制剂ACY-957：给药时间表对猴子体内药代动力学（PK），药效学（PD），造血毒性和伽马球蛋白（HBG）表达的影响
2. 386 POSTER Pharmacokinetic (PK) and pharmacodynamic (PD) phase I study of an oral c-Met inhibitor ARQ197 reaches maximum tolerated dose (MTD) in a twice daily (bid) dosing schedule [J] . T.A.Yap, J.Barriuso, S.Frentzas, European Journal of Cancer Supplements . 2008,第12期

机译：386口服c-Met抑制剂ARQ197的POSTER药代动力学（PK）和药效学（PD）I期研究在每日两次（出价）给药方案中达到最大耐受剂量（MTD）
3. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification [J] . Daniel Moj, Hannah Britz, Jürgen Burhenne, Cancer chemotherapy and pharmacology. . 2017,第5期

机译：组蛋白脱乙酰酶（HDAC）抑制剂Vorinostat的生理基础的药代动力学和药物动力学（PBPK / PD）模型用于儿科和成年患者及其剂量规格的应用及应用
4. Pharmacokinetics, pharmacodynamics, metabolism, transport, and resistance studies of a novel histone deacetylase inhibitor FK228 (FR901228, NSC630176). [D] . Xiao, Jin. 2004

机译：新型组蛋白脱乙酰基酶抑制剂FK228（FR901228，NSC630176）的药代动力学，药效学，代谢，转运和抗药性研究。
5. A physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification [O] . Daniel Moj, Hannah Britz, Jürgen Burhenne, -1

机译：组蛋白脱乙酰基酶（HDAC）抑制剂伏立诺他用于儿科和成年患者的基于生理的药代动力学和药效学（PBPK / PD）模型及其在剂量规范中的应用
6. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification [O] . Daniel Moj, Hannah Britz, Jürgen Burhenne, 2017

机译：用于儿科和成人患者的组蛋白脱乙酰酶（HDAC）抑制剂Vorinostat的生理学上的药代动力学和药效学（PBPK / PD）模型及其用于剂量规格的应用

The Histone Deacetylase 1 and 2 (HDAC1/2) Inhibitor ACY-957: Impact of Dosing Schedule on Pharmacokinetics (PK), Pharmacodynamics (PD), Hematopoietic Toxicity, and Gamma Globin (HBG,.) Expression in Monkey

著录项

引文网络

相似文献

相关主题

期刊订阅